
Annual report 2026
added 03-03-2026
STAAR Surgical Company Financial Statements 2011-2026 | STAA
Annual Financial Statements STAAR Surgical Company
| 2026 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
941 M | 832 M | 1.59 B | 1.58 B | 3.43 B | 1.58 B | - | 1.62 B | 675 M | 256 M | 229 M | 634 M | - | 191 M | 416 M |
Shares |
49.6 M | 49.1 M | 48.5 M | 48 M | 47.2 M | 46.9 M | - | 45.3 M | 41 M | 39.3 M | 38.1 M | 38.6 M | - | 36.3 M | 36.9 M |
Historical Prices |
19 | 16.9 | 32.8 | 32.8 | 72.7 | 103 | 33.6 | 35.7 | 15.7 | 9.9 | 6.53 | 6 | 16.4 | 5.66 | 10.9 |
Net Income |
-80.4 M | -20.2 M | 21.3 M | 39.7 M | 27.5 M | 14 M | - | 4.97 M | -2.14 M | -6.53 M | -8.39 M | 400 K | - | -1.8 M | 1.3 M |
Revenue |
239 M | 314 M | 322 M | 284 M | 230 M | 150 M | - | 124 M | 90.6 M | 77.1 M | 75 M | 72.2 M | - | 63.8 M | 62.8 M |
Cost of Revenue |
57 M | 74.3 M | 69.8 M | 61 M | 51.8 M | 38.2 M | - | 32.4 M | 26.3 M | 24.1 M | 26.2 M | 21.9 M | - | 19.5 M | 20.4 M |
Gross Profit |
182 M | 240 M | 253 M | 223 M | 179 M | 112 M | - | 91.5 M | 64.3 M | 52.7 M | 48.8 M | 50.3 M | - | 44.3 M | 42.4 M |
Operating Income |
-91.7 M | -12.6 M | 28.1 M | 43.8 M | 33.3 M | 11.9 M | - | 6.6 M | -3.63 M | -12.7 M | -8.03 M | 700 K | - | -1.22 M | 2.78 M |
Interest Expense |
2.25 M | 815 K | 448 K | 205 K | -48 K | 152 K | - | 82 K | 112 K | 115 K | 154 K | 170 K | - | 291 K | 523 K |
EBITDA |
-83.4 M | -5.72 M | 33.2 M | 48.3 M | 36.9 M | 15.6 M | - | 9.06 M | -277 K | -2.94 M | -5.57 M | 2.85 M | - | 760 K | 5.07 M |
Operating Expenses |
- | - | - | - | - | 100 M | - | 84.9 M | 67.9 M | 58.1 M | 56.8 M | 49.6 M | - | 45.5 M | 39.6 M |
General and Administrative Expenses |
85.8 M | 89.9 M | 72.3 M | 54.7 M | 44.1 M | 29.3 M | - | 24.3 M | 20.7 M | 19.6 M | 18.5 M | 18.8 M | - | 21.4 M | 16 M |
All numbers in USD currency
Quarterly Income Statement STAAR Surgical Company
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
49.6 M | 49.5 M | 49.3 M | 49.3 M | 49.2 M | 49.1 M | 48.9 M | 48.8 M | 48.6 M | 48.4 M | 48.2 M | 48.2 M | 48.1 M | 47.9 M | 47.8 M | 47.7 M | 47.5 M | 47.1 M | 46.6 M | 44.8 M | 45.9 M | 45.4 M | 45 M | - | 44.6 M | 44.5 M | 44.2 M | 44.2 M | 43.1 M | 41.7 M | 41.4 M | 41.4 M | 41.1 M | 40.9 M | 40.7 M | 40.7 K | 40.5 M | 40.2 M | 40 M | 38.4 K | 39.7 M | 39.1 M | 38.5 M | 37.9 K | 38.4 M | 38.2 M | 37.8 M | - | 36.8 M | 36.5 M | 36.4 M | 36.4 M | 36.3 M | 36.3 M | 36.1 M | 36 M | 35.5 M | 35.4 M | 35.2 M |
Net Income |
8.88 M | -16.8 M | -54.2 M | - | 9.98 M | 7.38 M | -3.34 M | - | 4.82 M | 6.06 M | 2.71 M | - | 10.3 M | 13 M | 9.6 M | 4.92 M | 6.02 M | 8.57 M | 4.99 M | 6.38 M | 3.89 M | -1.17 M | -134 K | - | 2.39 M | 3.91 M | 1.37 M | 1.1 M | 1.46 M | 1.83 M | 583 K | -138 K | 1.17 M | -971 K | -2.2 M | -167 K | -1.78 M | -2.14 M | -8.04 M | -2.54 M | -1.75 M | -1.6 M | -2.34 M | -876 K | -2.71 M | -1.79 M | -1.36 M | - | 525 K | 278 K | 471 K | -1.41 M | -90 K | -491 K | 232 K | 109 K | 77 K | 861 K | 300 K |
Revenue |
94.7 M | 44.3 M | 42.6 M | - | 88.6 M | 99 M | 77.4 M | - | 80.3 M | 92.3 M | 73.5 M | - | 76 M | 81.1 M | 63.2 M | 59 M | 58.4 M | 62.4 M | 50.8 M | 38.9 M | 47.1 M | 35.2 M | 35.2 M | - | 39.1 M | 39.7 M | 32.6 M | 31.2 M | 31.8 M | 33.9 M | 27.1 M | 24.9 M | 23.5 M | 21.9 M | 20.4 M | 22.1 M | 20.1 M | 21 M | 19.3 M | 16.6 M | 18.8 M | 18.7 M | 18.9 M | 18.9 M | 18.2 M | 20 M | 20.2 M | - | 17.1 M | 18.2 M | 18 M | 16.5 M | 15.9 M | 15.9 M | 15.5 M | 16.4 M | 15.3 M | 16.3 M | 14.8 M |
Cost of Revenue |
16.9 M | 11.5 M | 14.6 M | - | 20.1 M | 20.6 M | 16.3 M | - | 16.7 M | 21.6 M | 16 M | - | 15.6 M | 17.2 M | 13.9 M | - | 13.1 M | 13.2 M | 11.6 M | - | 12.2 M | 10.8 M | 10.4 M | - | 10 M | 9.76 M | 8.4 M | - | 7.91 M | 8.68 M | 7.66 M | - | 6.62 M | 6.46 M | 5.77 M | - | 5.18 M | 6.35 M | 6.28 M | - | 5.95 M | 6.3 M | 5.96 M | - | 6.32 M | 6.38 M | 6.29 M | - | 5.05 M | 5.54 M | 5.35 M | - | 4.69 M | 4.9 M | 4.61 M | - | 4.82 M | 5.41 M | 5.22 M |
Gross Profit |
77.9 M | 32.8 M | 28 M | - | 68.5 M | 78.4 M | 61 M | - | 63.6 M | 70.7 M | 57.6 M | - | 60.5 M | 63.9 M | 49.3 M | 45 M | 45.3 M | 49.2 M | 39.1 M | 28.8 M | 34.9 M | 24.4 M | 24.8 M | - | 29.1 M | 29.9 M | 24.2 M | 23 M | 23.9 M | 25.2 M | 19.4 M | 17.4 M | 16.8 M | 15.5 M | 14.6 M | 15.9 M | 14.9 M | 14.6 M | 13 M | 9.4 M | 12.8 M | 12.4 M | 12.9 M | 13 M | 11.9 M | 13.7 M | 13.9 M | - | 12.1 M | 12.6 M | 12.7 M | 11.2 M | 11.2 M | 11 M | 10.9 M | 11.4 M | 10.4 M | 10.9 M | 9.63 M |
Operating Income |
18.5 M | -30 M | -57.4 M | - | 5.68 M | 11.9 M | -2.28 M | - | 6.3 M | 8.6 M | 2.8 M | - | 13.7 M | 17 M | 12.1 M | - | 7.84 M | 10.6 M | 7.47 M | - | 4.88 M | -1.06 M | -1.14 M | - | 3.33 M | 4.61 M | 1.56 M | - | 1.58 M | 3.03 M | 799 K | - | 1.04 M | -1.32 M | -2.08 M | - | -1.72 M | -2.14 M | -10.1 M | - | -2.02 M | -1.74 M | -1.51 M | - | -1.55 M | -1.39 M | -1.34 M | - | 173 K | 694 K | 1.08 M | - | -91 K | -164 K | 278 K | - | 737 K | 1.17 M | 208 K |
Interest Expense |
353 K | 120 K | 131 K | - | 139 K | 63 K | 330 K | - | 71 K | 10 K | 63 K | - | 27 K | 89 K | 62 K | - | -13 K | 51 K | -85 K | - | -63 K | -21 K | 1 K | - | 26 K | 1 K | 97 K | - | 40 K | 4 K | 17 K | - | 27 K | 32 K | 28 K | - | 29 K | 29 K | 28 K | - | 29 K | 33 K | 36 K | - | 35 K | 34 K | 33 K | - | 38 K | 41 K | 83 K | - | 65 K | 67 K | 95 K | - | 134 K | 153 K | 153 K |
EBITDA |
- | - | -55.1 M | - | - | - | -1.04 M | - | - | - | 3.91 M | - | 16.8 M | 19 M | 13.1 M | - | 10.5 M | 12.4 M | 8.34 M | - | 7.16 M | 463 K | -369 K | - | 6.19 M | 6.59 M | 2.79 M | - | 3.38 M | 4.19 M | 1.35 M | - | 3.39 M | 228 K | -1.33 M | - | 218 K | -905 K | -9.46 M | - | -459 K | -747 K | -1.01 M | - | -33 K | -409 K | -889 K | - | 1.5 M | 1.53 M | 1.45 M | - | 898 K | 463 K | 595 K | - | 1.63 M | 1.77 M | 515 K |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.8 M | - | - | - | 16.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
20.8 M | 21 M | 24.5 M | - | 21.7 M | 23.6 M | 23.2 M | - | 19.3 M | 18.1 M | 18.1 M | - | 14 M | 14 M | 11.9 M | - | 11 M | 11.4 M | 10.2 M | - | 8.59 M | 7.85 M | 7.97 M | - | 7.1 M | 7.51 M | 6.84 M | - | 6.09 M | 6.2 M | 5.77 M | - | 4.72 M | 4.68 M | 5.35 M | - | 4.98 M | 4.93 M | 8.46 M | - | 4.85 M | 4.74 M | 5.16 M | - | 3.26 M | 5.37 M | 5.4 M | - | 4.14 M | 3.92 M | 3.96 M | - | 3.45 M | 3.63 M | 555 K | - | 3.68 M | 3.9 M | 133 K |
All numbers in USD currency
Main types of financial statements STAAR Surgical Company STAAFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting STAAR Surgical Company plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
Becton, Dickinson and Company
BDX
|
$ 154.51 | -1.17 % | $ 44.4 B | ||
|
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | ||
|
Repligen Corporation
RGEN
|
$ 117.78 | -0.46 % | $ 6.56 M | ||
|
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | ||
|
Ekso Bionics Holdings
EKSO
|
$ 9.4 | -11.74 % | $ 22.8 M | ||
|
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | ||
|
Haemonetics Corporation
HAE
|
$ 56.83 | 1.05 % | $ 2.86 B | ||
|
ICU Medical
ICUI
|
$ 123.31 | -1.53 % | $ 3.04 B | ||
|
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | ||
|
Intuitive Surgical
ISRG
|
$ 452.07 | -2.67 % | $ 161 B | ||
|
Harvard Bioscience
HBIO
|
$ 5.2 | 2.16 % | $ 231 M | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
AngioDynamics
ANGO
|
$ 10.31 | -13.65 % | $ 421 M | ||
|
Repro Med Systems
KRMD
|
$ 4.32 | 1.17 % | $ 200 M | ||
|
AtriCure
ATRC
|
$ 29.07 | 2.68 % | $ 1.39 B | ||
|
Pulse Biosciences
PLSE
|
$ 23.0 | -0.13 % | $ 1.55 B | ||
|
InfuSystem Holdings
INFU
|
$ 9.29 | -0.11 % | $ 192 M | ||
|
Masimo Corporation
MASI
|
$ 178.59 | 0.33 % | $ 9.52 B | ||
|
iRhythm Technologies
IRTC
|
$ 116.8 | -1.2 % | $ 3.74 B | ||
|
Merit Medical Systems
MMSI
|
$ 67.7 | -0.78 % | $ 4 B | ||
|
BioLife Solutions
BLFS
|
$ 19.51 | 1.14 % | $ 899 M | ||
|
electroCore
ECOR
|
$ 6.8 | 3.03 % | $ 57.7 K | ||
|
STERIS plc
STE
|
$ 218.71 | -0.56 % | $ 21.6 B | ||
|
Teleflex Incorporated
TFX
|
$ 117.81 | -0.52 % | $ 5.26 B | ||
|
Utah Medical Products
UTMD
|
$ 63.12 | 0.4 % | $ 205 M | ||
|
OraSure Technologies
OSUR
|
$ 3.08 | 0.98 % | $ 226 M | ||
|
West Pharmaceutical Services
WST
|
$ 254.8 | 0.82 % | $ 18.4 B | ||
|
DENTSPLY SIRONA
XRAY
|
$ 11.63 | -0.26 % | $ 2.32 B | ||
|
Glaukos Corporation
GKOS
|
$ 112.77 | 0.12 % | $ 5.46 B | ||
|
ResMed
RMD
|
$ 224.09 | 0.56 % | $ 32.7 B | ||
|
Predictive Oncology
POAI
|
- | - | $ 31.1 M | ||
|
Baxter International
BAX
|
$ 16.68 | -0.6 % | $ 8.56 B | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
Stereotaxis
STXS
|
$ 1.87 | 1.08 % | $ 170 M | ||
|
The Cooper Companies
COO
|
$ 70.17 | -1.76 % | $ 14 B | ||
|
LeMaitre Vascular
LMAT
|
$ 108.49 | -0.24 % | $ 2.46 B | ||
|
Microbot Medical
MBOT
|
$ 2.4 | 1.27 % | $ 110 M | ||
|
Nephros
NEPH
|
$ 2.87 | -2.21 % | $ 29.8 M | ||
|
Envista Holdings Corporation
NVST
|
$ 25.81 | -0.35 % | $ 4.34 B | ||
|
Milestone Scientific
MLSS
|
$ 0.28 | -4.86 % | $ 23 M | ||
|
Alcon
ALC
|
$ 74.56 | -1.26 % | $ 40.4 B | ||
|
Pro-Dex
PDEX
|
$ 51.67 | 1.33 % | $ 170 M | ||
|
Retractable Technologies
RVP
|
$ 0.69 | 2.99 % | $ 20.7 M |